Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AXL activation can promote resistance to MEK inhibition in a model of colorectal cancer (CRC)

Date

10 Oct 2016

Session

Poster display

Presenters

Giulia Martini

Citation

Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362

Authors

G. Martini1, V. Belli2, P.P. Vitiello1, T. Troiani1, C. Cardone1, S. Napolitano1, V. Sforza3, M.L. Ferrara1, F. Morgillo1, D. Ciardiello1, E.F. Giunta1, F. Ciardiello1, E. Martinelli1

Author affiliations

  • 1 Medical Oncology, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 81131 - Napoli/IT
  • 2 Medical Oncology P.o. Edificio 3, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 80131 - Napoli/IT
  • 3 Medical Oncology, AOU Seconda Università degli Studi di Napoli (AOU-SUN), 81130 - Napoli/IT
More

Resources

Background

In metastatic colorectal cancer (mCRC) the presence of intrinsic and the development of acquired resistance to target therapy represent the most unsolved problems in the treatment of patients. The RAS/RAF/MEK/MAPK signalling pathway plays central roles in the intracellular transduction of proliferative signals from activated cell membrane growth factor receptors to the nucleus in cancer cells. MEK activation is an important convergence point involved in the development of drug resistance in mCRC setting. AXL, a tyrosine kinase receptor, plays important roles for cancer progression, invasion, metastasis and drug resistance. We did this preclinical study to evaluate a possible mechanism of MEK acquired resistance.

Methods

CRC (HCT116 and LOVO) cell lines were used. We generated in vitro HCT116 and LOVO cell lines resistant to the MEK inhibitor refametinib. Expression and activation of intracellular pathway were analysed by Western Blot (WB). The effect of foretinib, R428 and S49076 (AXL inhibitors) were evaluated by MTT assay. Cell cycle and apoptosis were analysed by flow cytometry. Chambers of transwell were used to evaluate the migratory capacity.

Results

We generated, HCT116 and LOVO clones (MEK-R) resistant to refametinib after continuous one-year drug exposure. MEK-R CRC cells have an IC50 value 50 and 100 times higher than parental cells, respectively. We found in the resistant clones a strong activation of pAXL and its downstream pathway (in particular pAKT). Treatment of resistant clones with the different concentrations of AXL inhibitors was able to reduce cell viability accompanied by a marked deregulation of activation of AXL, AKT and MAPK. Further experiments on cell cycle, apoptosis and migration are still ongoing and will be presented.

Conclusions

Our in vitro preliminary data demonstrate AXL activation as a potential mechanism of resistance to MEK inhibition, and suggest a treatment with AXL inhibitors as a clinical strategy to possibly prevent this mechanism of resistance in CRC.

Clinical trial identification

Legal entity responsible for the study

Second University of Naples

Funding

AIRC

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings